Ma Li,Pan Jinbin,Shu Gang,Pan Haiyan,Li Jingang,Li Dong,Sun Shaokai
Enhanced computed tomography (CT) imaging with iodinated imaging probes is widely utilized for the diagnosis and evaluation of various liver diseases. However, these iodine-based imaging probes face intractable limitations including allergic reactions and contraindications. Herein, we propose the utilization of renal-clearable iodine-free bismuth chelate (Bi-DTPA dimeglumine) for the non-invasive fast assessment of hepatic ischemia–reperfusion injury (HIRI) via CT imaging for the first time. Bi-DTPA dimeglumine offers several advantages such as simple synthesis, no purification requirement, a yield approaching 100%, large-scale production capability (laboratory synthesis > 100 g), excellent biocompatibility and superior CT imaging performance. In a normal rat model, the administration of Bi-DTPA dimeglumine resulted in a significant 63.79% increase in liver CT value within a very short time period (30 s). Furthermore, in a HIRI rat model, Bi-DTPA dimeglumine enabled the rapid differentiation between healthy and injured areas based on the notable disparity in liver CT values as early as 15 min post-reperfusion, which showed a strong correlation with the histopathological analysis results. Additionally, Bi-DTPA dimeglumine can be almost eliminated from the body via the kidneys within 24 h. As an inherently advantageous alternative to iodinated imaging probes, Bi-DTPA dimeglumine exhibits promising prospects for application in liver disease diagnosis.
Operative microwave ablation (MWA) has become a superior curative treatment modality for unresectable hepatocellular carcinoma (HCC). However, rapid noninvasive assessment of the MWA outcomes of HCC patients remains technically challenging. Herein, a surface-enhanced Raman spectroscopy (SERS)-lateral flow strip (LFS) immunosensor is reported for simultaneous quantification of two serum protein biomarkers – (C-C motif chemokine ligand 20) CCL20 and epidermal growth factor (EGF) proteins, which enables rapid noninvasive assessment of operative MWA outcomes of HCC patients. This biosensor is built with two test lines for CCL20 and EGF proteins using the encoded SERS probes, respectively. The integration of the SERS detection and the lateral flow immunoassay detection format yields high sensitivity, robust anti-interference ability, and ease-to-use. This biosensor achieves a limit of detection down to 0.064 ng/mL for CCL20 protein and 0.090 ng/mL for EGF protein with a wide dynamic detection range. Moreover, the SERS-LFS immunosensor is demonstrated with exceptional performance for quantitative detection of CCL20 and EGF proteins in clinical serum samples in a single test strip. The results reveal the discriminative levels of CCL20 and EGF proteins in serum samples of HCC patients undergoing complete and incomplete MWA, verifying the capability of our developed biosensor for rapid assessment of MWA outcomes. We believe that the developed SERS-LFS immunosensor could be applied to support medical professionals in clinical settings for improvement of MWA outcomes of HCC patients.
Fangkun Yang,Jie Cao,Xiaoxue Jia,Hailiang Zhu,Jieli Zhou,Zhaocheng Liu,Hanbin Cui,Kai Wang
Cardiovascular diseases (CVDs) pose a serious threat to human health, with atherosclerosis being a leading cause of heart disease and stroke. Elevated cysteine (Cys) levels have been closely linked to an increased risk of cardiovascular diseases, underscoring its significance in cardiovascular health. However, current detection methods for cysteine in serum and atherosclerotic plaques present challenges in sensitivity, specificity, dynamic monitoring, and invasiveness. The development of more sensitive, specific, and noninvasive assays is needed to enable accurate monitoring of cysteine levels. This study introduces the development and characterization of Cys-NPs, a sensitive and selective tool for imaging cysteine in foam cells and atherosclerotic mice. Encapsulation of the HD-probe using DSPE-PEG to obtain Cys-NPs effectively reduced interference from glutathione (GSH), leading to successful preparation and validation of Cys-NPs’s nanoscale structure. At the same time, Cys-NPs was able to use the differences in Hcy and Cys concentrations in vivo to better assess Cys levels in vivo. In vitro and in vivo studies demonstrated Cys-NPs’s effective imaging of cysteine in foam cells and atherosclerotic mice, highlighting its potential for noninvasive assessment of cysteine levels in ischemic heart disease research and clinical practice.
危险品化学品经营许可证（带存储）